[go: up one dir, main page]

RU2001111025A - Фармацевтическая композиция для лечения острых нарушений - Google Patents

Фармацевтическая композиция для лечения острых нарушений

Info

Publication number
RU2001111025A
RU2001111025A RU2001111025/15A RU2001111025A RU2001111025A RU 2001111025 A RU2001111025 A RU 2001111025A RU 2001111025/15 A RU2001111025/15 A RU 2001111025/15A RU 2001111025 A RU2001111025 A RU 2001111025A RU 2001111025 A RU2001111025 A RU 2001111025A
Authority
RU
Russia
Prior art keywords
composition according
cellulose
agent
composition
microparticles
Prior art date
Application number
RU2001111025/15A
Other languages
English (en)
Other versions
RU2193879C1 (ru
Inventor
Андерс ПЕТТЕРССОН (SE)
Андерс Петтерссон
Кристер НЮСТРЕМ (SE)
Кристер НЮСТРЕМ
Original Assignee
Диабакт Аб (Se)
Диабакт Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20412702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2001111025(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Диабакт Аб (Se), Диабакт Аб filed Critical Диабакт Аб (Se)
Application granted granted Critical
Publication of RU2193879C1 publication Critical patent/RU2193879C1/ru
Publication of RU2001111025A publication Critical patent/RU2001111025A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)

Claims (21)

1. Фармацевтическая композиция для лечения острых нарушений путем подъязычного введения, содержащая существенно безводную смесь микрочастиц по меньшей мере одного фармацевтически активного агента, прикрепленного к поверхности частиц носителя, причем указанные частицы значительно больше, чем указанные микрочастицы, и являются водорастворимыми, и агента, усиливающего биоадгезию и/или мукоадгезию, в основном прикрепленного к поверхности частиц носителя.
2. Композиция по п.1, отличающаяся тем, что микрочастицы указанного активного агента или агентов имеют на основе массы средний диаметр менее 10 мкм.
3. Композиция по п.1 или 2, отличающаяся тем, что средний диаметр частиц носителя после гель-фильтрации составляет менее 750 мкм, предпочтительно от 100 до 600 мкм.
4. Композиция по любому из пп.1-4, отличающаяся тем, что частицы носителя содержат хрупкий материал, который легко фрагментируется при прессовании.
5. Композиция по любому из пп.1-4, отличающаяся тем, что частицы носителя содержат от 0,1 до 25 вес.% агента, усиливающего био/мукоадгезию, предпочтительно от 1 до 13 вес.% от всей композиции.
6. Композиция по п.5, отличающаяся тем, что агент, усиливающий био/мукоадгезию, выбран из группы, состоящей из акриловых полимеров, производных целлюлозы, естественных полимеров, имеющих био/мукоадгезивные свойства, и их смесей.
7. Композиция по п.6, отличающаяся тем, что агент, усиливающий био/мукоадгезию, выбран из группы, состоящей из производных целлюлозы и включающей в себя гидроксипропилметилцеллюлозу, гидроксиэтилцеллюлозу, гидроксипропилцеллюлозу, натрий-карбоксиметилцеллюлозу, метилцеллюлозу, этилгидроксиэтилцеллюлозу, карбоксиметилцеллюлозу, микрокристаллическую целлюлозу и модифицированную целлюлозную смолу; кросскарамеллозу; модифицированный крахмал; акриловые полимеры, включая карбомер и его производные; полиэтиленоксид; хитозан; желатин; алгинат натрия; пектин; склероглюкан; ксантановую камедь; гуар-гум; поли-со-(метил)виниловый эфир-малеиновый ангидрид); и их смеси.
8. Композиция по любому одному из пп.1-7, отличающаяся тем, что дополнительно содержит фармацевтически приемлемое поверхностно-активное вещество в мелкодисперсной форме, однородно смешанное с активным агентом или агентами.
9. Композиция по п.8, отличающаяся тем, что поверхностно-активное вещество присутствует в количестве от 0,5 до 5 вес.% от композиции, предпочтительно от 0,5 до 3 вес.%.
10. Композиция по п.8 или 9, отличающаяся тем, что поверхностно-активное вещество выбрано из группы, состоящей из лаурилсульфата натрия, полисорбатов, солей желчных кислот и их смесей.
11. Композиция по любому из пп.1-10, отличающаяся тем, что частицы носителя содержат водорастворимый, фармацевтически приемлемый углевод и/или неорганическую соль.
12. Композиция по п.11, отличающаяся тем, что частицы носителя содержат по меньшей мере одно из следующих веществ: маннит, лактозу, фосфат кальция и сахар.
13. Композиция по любому из пп.1-12, отличающаяся тем, что частицы носителя содержат по меньшей мере один фармацевтический дезинтегрирующий агент, способствующий распространению микрочастиц активного агента или агентов по сублингвальной слизистой.
14. Композиция по п.13, отличающаяся тем, что дезинтегрирующий агент выбран из группы, состоящей из поперечно-связанного поливинилпирролидона, карбоксиметил крахмала, естественного крахмала, микрокристаллической целлюлозы, целлюлозной смолы и их смесей.
15. Композиция по п.13 или 14, отличающаяся тем, что дезинтегрирующий агент присутствует в количестве от 1 до 10 вес.% от композиции.
16. Композиция по любому из пп.1-15, отличающаяся тем, что фармацевтически активный агент представляет собой фентанил или его фармацевтически приемлемую соль.
17. Композиция по любому из пп.1-16 для лечения острых нарушений путем подъязычного введения.
18. Композиция по п.16 для лечения острой и перемежающейся боли путем подъязычного введения фентанила или его фармацевтически приемлемой соли.
19. Способ лечения острых нарушений, при котором индивидууму, страдающему указанным нарушением, вводится подъязычно по меньшей мере одна стандартная доза существенно безводной фармацевтической композиции, содержащей эффективное количество по меньшей мере одного фармацевтически активного агента в виде микрочастиц, прикрепленных к поверхности частиц носителя, которые значительно больше, чем указанные микрочастицы, и в основном являются водорастворимыми, и агента, усиливающего биоадгезию и/или мукоадгезию.
20. Способ по п.19, отличающийся тем, что фармацевтически активный агент является фентанилом или его фармацевтически приемлемой солью.
21. Способ по п.20, отличающийся тем, что фентанил вводят в количестве от 0, 05 до 20 мг, предпочтительно от 0,1 до 5 мг на стандартную дозу.
RU2001111025/14A 1998-09-24 1999-09-24 Фармацевтическая композиция для лечения острых нарушений RU2193879C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9803240A SE9803240D0 (sv) 1998-09-24 1998-09-24 A pharmaceutical composition having a rapid action
SE9803240-2 1998-09-24

Publications (2)

Publication Number Publication Date
RU2193879C1 RU2193879C1 (ru) 2002-12-10
RU2001111025A true RU2001111025A (ru) 2004-02-20

Family

ID=20412702

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001111025/14A RU2193879C1 (ru) 1998-09-24 1999-09-24 Фармацевтическая композиция для лечения острых нарушений

Country Status (29)

Country Link
US (8) US6761910B1 (ru)
EP (5) EP1652518B1 (ru)
JP (1) JP3381220B2 (ru)
KR (1) KR100760536B1 (ru)
CN (1) CN1173694C (ru)
AT (1) ATE365540T1 (ru)
AU (1) AU764346B2 (ru)
BG (1) BG65502B1 (ru)
BR (1) BRPI9913945B8 (ru)
CA (3) CA2820588C (ru)
CY (5) CY1107711T1 (ru)
CZ (2) CZ302975B6 (ru)
DE (1) DE69936393T2 (ru)
DK (5) DK2236133T3 (ru)
EE (3) EE04927B1 (ru)
ES (5) ES2289829T3 (ru)
HU (2) HU230342B1 (ru)
IL (1) IL142135A0 (ru)
LU (1) LU92636I2 (ru)
MX (1) MXPA01003068A (ru)
NO (1) NO332226B1 (ru)
NZ (1) NZ510284A (ru)
PL (2) PL201644B1 (ru)
PT (5) PT2236133E (ru)
RU (1) RU2193879C1 (ru)
SE (1) SE9803240D0 (ru)
SK (1) SK283302B6 (ru)
TR (1) TR200100855T2 (ru)
WO (1) WO2000016750A1 (ru)

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US20030118645A1 (en) * 1998-04-29 2003-06-26 Pather S. Indiran Pharmaceutical compositions for rectal and vaginal administration
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
CN100346788C (zh) 2000-07-31 2007-11-07 尼科梅德丹麦有限公司 用于鼻内给药的芬太尼组合物
BR0115986A (pt) * 2000-12-07 2003-12-23 Altana Pharma Ag Comprimido de desintegração rápida contendo um ingrediente ativo instável aos ácidos
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
JP4850346B2 (ja) * 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20030165566A1 (en) * 2002-01-10 2003-09-04 O'toole Edel Sedative non-benzodiazepine formulations
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
EP2085072A1 (en) * 2002-03-26 2009-08-05 Teva Pharmaceutical Industries Ltd. Drug microparticles
ES2199061B1 (es) * 2002-06-10 2005-02-16 Laboratorios Vita, S.A. Comprimidos bucodispersables y procedimiento para su obtencion.
GB0217056D0 (en) * 2002-07-23 2002-08-28 Ass Octel Use
CA2507522C (en) 2002-12-13 2015-02-24 Durect Corporation Oral drug delivery system
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
ES2270335T7 (es) * 2003-01-31 2012-03-16 Orexo Ab Composicion farmaceuta de efecto.
BR0302017B1 (pt) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Composição farmacêutica sublingual a base de um agonista do receptor central de benzodiazepínicos
ITRM20030288A1 (it) * 2003-06-10 2004-12-11 Valerio Cioli Somministrazione sublinguale di antinfiammatori non steroidei (fans)
US20060241037A1 (en) * 2003-10-03 2006-10-26 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump ihhibitor prodrugs
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
BRPI0418228B8 (pt) * 2003-12-31 2021-05-25 Cima Labs Inc forma de dosagem, e, método de preparação de um tablete para administração bucal, gengival ou sublingual de fentanil
WO2005065317A2 (en) 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
JP5244318B2 (ja) 2003-12-31 2013-07-24 シーマ・ラブス、インコーポレイテッド 発泡性経口アヘン薬投薬形態およびアヘン薬の投与方法
JP5179757B2 (ja) * 2004-02-17 2013-04-10 トランセプト ファーマシューティカルズ， インコーポレイティド 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
US8163114B2 (en) * 2004-04-07 2012-04-24 New Jersey Institute Of Technology Netshape manufacturing processes and compositions
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
LT2422789T (lt) * 2004-05-19 2018-03-12 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Injekcinės kompozicijos, apimančios natrio deoksicholiatą
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
GB0423800D0 (en) 2004-10-27 2004-12-01 Orexo Ab New pharmaceutical formulations
US20060278558A1 (en) * 2005-01-14 2006-12-14 Michelle Nivala Non-tearable child resistant blister package
ES2375974T3 (es) * 2005-01-14 2012-03-07 Cima Labs Inc. Envase de pastillas del tipo de doblar y despegar.
AU2006212021B2 (en) * 2005-02-10 2010-09-30 Orexo Ab Pharmaceutical compositions useful in the transmucosal administration of drugs
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
EP1863456A1 (en) * 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of pain
EP1863455A1 (en) * 2005-03-28 2007-12-12 Orexo AB New pharmaceutical compositions useful in the treatment of parkinson's disease
JP2008534562A (ja) * 2005-03-28 2008-08-28 オレクソ・アクチエボラゲット 偏頭痛の治療に有用な新しい製薬組成物
US20060281783A1 (en) * 2005-05-25 2006-12-14 Transoral Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070287740A1 (en) * 2005-05-25 2007-12-13 Transcept Pharmaceuticals, Inc. Compositions and methods of treating middle-of-the night insomnia
US20070225322A1 (en) * 2005-05-25 2007-09-27 Transoral Pharmaceuticals, Inc. Compositions and methods for treating middle-of-the night insomnia
CN101198327B (zh) * 2005-05-25 2012-06-20 特兰斯塞普特制药公司 治疗半夜失眠的固体组合物和方法
TWI383809B (zh) * 2005-06-29 2013-02-01 Otsuka Pharma Co Ltd 含有西洛他唑（ｃｉｌｏｓｔａｚｏｌ）之口腔崩解粉末
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
EP1976521B1 (en) * 2006-01-25 2015-03-11 Insys Therapeutics, Inc. Sublingual fentanyl spray
BRPI0709872A2 (pt) * 2006-04-03 2011-07-26 Teva Pharma micropartÍculas de drogas
US20070260491A1 (en) * 2006-05-08 2007-11-08 Pamela Palmer System for delivery and monitoring of administration of controlled substances
ES2565629T3 (es) * 2006-05-23 2016-04-06 Orahealth Corporation Comprimido de adhesión oral bicapa con adhesivo de goma arábiga
US20070286900A1 (en) * 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
ITMI20061117A1 (it) * 2006-06-09 2007-12-10 Michele Bonanomi Una composizione farmaceutica per la somministrazione sublinguale di vaccini metodo per la sua preparazione e sui usi
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
JP5484062B2 (ja) 2006-12-04 2014-05-07 オレクソ・アクチエボラゲット オピオイドを含む新規の非−乱用性医薬組成物
WO2008070795A2 (en) * 2006-12-06 2008-06-12 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
WO2008077092A2 (en) 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
DE102007010109A1 (de) * 2007-02-28 2008-09-04 Henkel Ag & Co. Kgaa Wirkstoffträgersysteme
CA2679316C (en) * 2007-03-02 2016-11-29 Teika Pharmaceutical Co., Ltd. Morphine composition for transdermal absorption, morphine composition storing unit and transdermal absorption preparation using the same
WO2009076236A2 (en) * 2007-12-06 2009-06-18 Pain Therapeutics, Inc. Micronized opioid compositions, formulations and dosage forms and methods of making same
EP2067471B1 (en) 2007-12-06 2018-02-14 Durect Corporation Oral pharmaceutical dosage forms
WO2009098169A1 (en) * 2008-02-05 2009-08-13 Alpex Pharma Sa Orally disintegrating tablets with speckled appearance
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
EP2111857A1 (de) * 2008-04-25 2009-10-28 Acino AG Transdermales therapeutisches System zur Verabreichung von Fentanyl oder einem Analogstoff hiervon
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
SE533540C2 (sv) 2008-12-19 2010-10-19 Neoinvent Medical Engineering Ab Administrerinssystem för administrering av en substans i munhålan
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
JP5702526B2 (ja) 2009-04-30 2015-04-15 Ｅｓファイバービジョンズ株式会社 抗ウイルス性を有する硫酸化セルロースを担持させた繊維集合体
WO2011041414A1 (en) 2009-09-30 2011-04-07 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
US10744086B2 (en) 2009-10-30 2020-08-18 Ix Biopharma Ltd. Fast dissolving solid dosage form
WO2011080501A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
UA116615C2 (uk) 2010-07-02 2018-04-25 Юніверсіті Оф Вірджінія Петент Фаундейшн Застосування ондансетрону у лікуванні хвороби чи розладу, пов'язаних з алкоголем
ITMI20101426A1 (it) * 2010-07-29 2012-01-30 Altergon Sa Composizione contenente condroitin solfato
FR2967066B1 (fr) * 2010-11-04 2013-06-14 Ethypharm Sa Utilisation par voie sublinguale de microgranules non comprimes
WO2012106058A2 (en) * 2011-01-31 2012-08-09 New Market Pharmaceuticals Animal treatments
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US20140161827A1 (en) 2011-05-09 2014-06-12 University Of Virginia Patent Foundation Compositions and methods for treating cancer
EA027743B1 (ru) 2011-09-09 2017-08-31 Юниверсити Оф Вирджиния Пэтент Фаундейшн Молекулярно-генетический подход для лечения и диагностики алкогольной и наркотической зависимости
HUE056309T2 (hu) 2011-09-19 2022-02-28 Orexo Ab Buprenorfint és naloxont tartalmazó szublingvális, abúzus-rezisztens tabletták
AU2013255640B2 (en) 2012-05-02 2017-06-15 Orexo Ab New alfentanil composition for the treatment of acute pain
MX392839B (es) 2012-11-30 2025-03-24 Acura Pharmaceuticals Inc Liberacion autorregulada de ingrediente farmaceutico activo.
AU2014233453A1 (en) 2013-03-15 2015-10-01 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
US20160296463A1 (en) 2013-11-11 2016-10-13 Impax Laboratories, Inc. Rapidly disintegrating formulations and methods thereof
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3177146A4 (en) 2014-07-08 2018-01-03 Insys Pharma, Inc. Sublingual naloxone spray
NZ732808A (en) 2014-12-23 2021-12-24 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US11103581B2 (en) 2015-08-31 2021-08-31 Acura Pharmaceuticals, Inc. Methods and compositions for self-regulated release of active pharmaceutical ingredient
WO2017072774A1 (en) * 2015-10-29 2017-05-04 Solubest Ltd Pharmaceutical compositions for transmucosal delivery
US10946020B2 (en) 2016-04-06 2021-03-16 University Of Virginia Patent Foundation Compositions and methods for treating cancer
CA3028450A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
CN107157994A (zh) * 2017-06-09 2017-09-15 董鹏 一种托拉塞米的舌下口服制剂

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4206209A (en) * 1978-11-02 1980-06-03 Kracauer Paul Sublingual aspirin tablet
US4229447A (en) * 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4432975A (en) * 1981-04-13 1984-02-21 Icn Pharmaceuticals, Inc. Process for introducing vitamin B-12 into the bloodstream
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
GB8332556D0 (en) * 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
GB8522453D0 (en) * 1985-09-11 1985-10-16 Lilly Industries Ltd Chewable capsules
DE3715682A1 (de) * 1987-05-11 1988-11-24 Stefan Dr Lueth Vorrichtung zum herstellen eines zweikomponentengemisches
SE8800080L (sv) * 1988-01-13 1989-07-14 Kabivitrum Ab Laekemedelskomposition
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US4866046A (en) * 1988-05-31 1989-09-12 Top Laboratories, Inc. Low-dosage sublingual aspirin
US5047244A (en) * 1988-06-03 1991-09-10 Watson Laboratories, Inc. Mucoadhesive carrier for delivery of therapeutical agent
SE8803935L (sv) * 1988-10-31 1990-05-01 Kabivitrum Ab Laekemedelskomposition
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
EP0431519B1 (en) * 1989-12-04 1994-06-15 G.D. Searle & Co. System for transdermal albuterol administration
SE8904298D0 (sv) * 1989-12-21 1989-12-21 Astra Ab New compounds
US5370862A (en) * 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
RU2007729C1 (ru) * 1991-05-05 1994-02-15 Донецкий государственный медицинский институт им.М.Горького Способ дифференциальной диагностики острой почечной недостаточности и функциональной олигурии
US5173486A (en) * 1991-08-26 1992-12-22 Bristol-Myers Squibb Company Dibenz[b,f][1,4]oxazepin-11(10H)-ones for multidrug resistance reversing agents
FR2694194B1 (fr) 1992-07-31 1994-11-04 Health Business Dev Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel.
JPH0665103A (ja) 1992-08-13 1994-03-08 ▲寛▼治 ▲高▼田 向精神薬のための速吸収性舌下投与製剤
CA2145207A1 (en) 1992-09-21 1994-03-22 Bo-Yi Qin Methods for identifying and using low/non-addictive opioid analgesics
DE69429119T2 (de) 1993-07-09 2002-07-18 R.P. Scherer Corp., Troy Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
GB9401894D0 (en) * 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US5948389A (en) * 1995-06-07 1999-09-07 El Khoury & Stein, Ltd. Method of enhancing the analgesic efficacy of locally and topically administered opioids and other local anesthetics
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
DE19652268C2 (de) 1996-12-16 2000-06-29 Lohmann Therapie Syst Lts Arzneizubereitung für die Freisetzung von Apomorphin in der Mundhöhle
DE19652188C2 (de) 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19758564A1 (de) * 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
KR100289471B1 (ko) * 1998-01-19 2001-09-17 김충섭 휀타닐계마취제의이식형서방성제제
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US6264974B1 (en) * 1998-07-07 2001-07-24 Salvagnini Italia Spa Buccal and sublingual administration of physostigmine
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
EP1005863A1 (en) * 1998-12-04 2000-06-07 Synthelabo Controlled-release dosage forms comprising a short acting hypnotic or a salt thereof
AU7937500A (en) 1999-10-27 2001-05-08 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
CN1290525A (zh) 2000-10-10 2001-04-11 北京万全阳光医药科技有限公司 冷冻干燥的扎来普隆速溶口服组合物
US20030035839A1 (en) 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
KR20040099262A (ko) 2002-01-10 2004-11-26 바이오베일 라보라토리즈 인크. 비-벤조디아제핀계 진정제 제제
CN1418631A (zh) 2002-12-19 2003-05-21 王登之 治疗失眠的佐匹克隆口腔崩解片及其制备方法
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets

Also Published As

Publication number Publication date
ES2433930T3 (es) 2013-12-13
CZ306387B6 (cs) 2016-12-28
AU6492799A (en) 2000-04-10
PL347126A1 (en) 2002-03-25
NO20011473L (no) 2001-05-23
SK283302B6 (sk) 2003-05-02
RU2193879C1 (ru) 2002-12-10
CZ2008315A3 (cs) 2016-12-28
CA2820588C (en) 2015-11-17
PT1652518E (pt) 2013-10-01
TR200100855T2 (tr) 2001-10-22
NZ510284A (en) 2003-05-30
CN1173694C (zh) 2004-11-03
US20140030336A1 (en) 2014-01-30
US20120315331A1 (en) 2012-12-13
EP2236132A1 (en) 2010-10-06
HU230468B1 (hu) 2016-07-28
EP2805716A1 (en) 2014-11-26
CY1115688T1 (el) 2017-01-25
JP2002526439A (ja) 2002-08-20
DK1652518T3 (da) 2013-10-28
US20080286368A1 (en) 2008-11-20
CY1115685T1 (el) 2017-01-25
CZ302975B6 (cs) 2012-02-01
US8454996B2 (en) 2013-06-04
HU0800435D0 (en) 2008-09-29
PT2805716T (pt) 2017-12-21
HK1091722A1 (en) 2007-01-26
DK1115383T3 (da) 2007-07-30
HUP0103856A3 (en) 2003-11-28
WO2000016750A1 (en) 2000-03-30
CA2820588A1 (en) 2000-03-30
SE9803240D0 (sv) 1998-09-24
BG65502B1 (bg) 2008-10-31
CY1114620T1 (el) 2016-10-05
US20130195976A1 (en) 2013-08-01
EP1115383B1 (en) 2007-06-27
CY1107711T1 (el) 2013-04-18
EP1652518B1 (en) 2013-08-07
PL204264B1 (pl) 2009-12-31
CA2629988A1 (en) 2000-03-30
BR9913945B1 (pt) 2017-10-24
NO20011473D0 (no) 2001-03-22
KR20010075315A (ko) 2001-08-09
AU764346B2 (en) 2003-08-14
ATE365540T1 (de) 2007-07-15
CY1119644T1 (el) 2018-04-04
EE04927B1 (et) 2007-12-17
IL142135A0 (en) 2002-03-10
HK1148457A1 (en) 2011-09-09
EP2805716B1 (en) 2017-09-13
ES2498095T3 (es) 2014-09-24
HU230342B1 (hu) 2016-02-29
HK1148458A1 (en) 2011-09-09
EP2236132B1 (en) 2014-07-23
US20040213855A1 (en) 2004-10-28
CA2629988C (en) 2014-01-07
BRPI9913945B8 (pt) 2022-01-25
DK2236133T3 (da) 2014-07-14
ES2644770T3 (es) 2017-11-30
SK4022001A3 (en) 2001-11-06
EP1115383A1 (en) 2001-07-18
DE69936393D1 (de) 2007-08-09
EP2236133B1 (en) 2014-07-02
ES2507579T3 (es) 2014-10-15
BR9913945A (pt) 2001-06-12
EE200800028A (et) 2008-08-15
PT1115383E (pt) 2007-07-13
NO332226B1 (no) 2012-07-30
CZ20011029A3 (cs) 2001-08-15
DE69936393T2 (de) 2008-03-13
HUP0103856A2 (hu) 2002-02-28
EE05555B1 (et) 2012-08-15
PT2236133E (pt) 2014-07-16
DK2805716T3 (en) 2017-10-16
HK1203144A1 (en) 2015-10-23
PL201644B1 (pl) 2009-04-30
EE200100182A (et) 2002-08-15
MXPA01003068A (es) 2004-09-13
EE200700030A (et) 2007-08-15
CA2345121A1 (en) 2000-03-30
US7910132B2 (en) 2011-03-22
EP2236133A1 (en) 2010-10-06
KR100760536B1 (ko) 2007-10-04
BG105379A (en) 2001-12-29
JP3381220B2 (ja) 2003-02-24
DK2236132T3 (da) 2014-08-04
EE05023B1 (et) 2008-06-16
US6761910B1 (en) 2004-07-13
US8512747B2 (en) 2013-08-20
ES2289829T3 (es) 2008-02-01
PT2236132E (pt) 2014-07-31
CA2345121C (en) 2008-06-10
CN1326340A (zh) 2001-12-12
US20120315330A1 (en) 2012-12-13
US20070031502A1 (en) 2007-02-08
LU92636I2 (fr) 2015-03-20
EP1652518A1 (en) 2006-05-03

Similar Documents

Publication Publication Date Title
RU2001111025A (ru) Фармацевтическая композиция для лечения острых нарушений
RU2001111026A (ru) Композиция фентанила для лечения острой боли
RU2005127353A (ru) Быстродействующая фармацевтическая композиция
US6685951B2 (en) Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
KR100760531B1 (ko) 급성 통증 치료용 펜타닐 조성물
CA2190778C (en) Transmucosal delivery system
SI20360B (sl) Sredstva in metode za zdravljenje motenj v zvezi z neuravnovešenostjo ter hiperaktivnih motenj v zvezi z neuravnovešenostjo s pomočjo metilfenidata
JPH10511407A (ja) 高用量難溶性薬物用持続放出マトリックス
EP2263660A3 (en) Orally disintegrable tablets
US20030022910A1 (en) Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine
US20030017175A1 (en) Sublingual administration of dihydroergotamine for the treatment of migraine
EP1863454A2 (en) New pharmaceutical compositions useful in the treatment of migraine
AU619261B2 (en) Solid rapidly disintegrating dosage form
CA2374039A1 (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
US20080193526A1 (en) Pharmaceutical Compositions Useful in the Treatment of Pain
CA2386583A1 (en) Novel combination for the treatment of sexual dysfunction
AU2006228296A1 (en) New pharmaceutical compositions useful in the treatment of parkinson's disease
HK1203144B (en) A pharmaceutical composition comprising buprenorphine having a rapid action